Business Context and Reporting Period
This Form 6-K filing by Celsus Therapeutics PLC (noted as Akari Therapeutics Plc in metadata) is dated September 17, 2013. The report serves to notify the SEC of a corporate announcement regarding the trading status of the Company's American Depository Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a trading symbol change and does not contain financial statements or performance metrics.
Material Changes
- Trading Symbol Change: Effective September 16, 2013, the Company's ADRs commenced trading on the OTC Markets under the new symbol "CLSXY".
- Previous Symbol: The prior trading symbol was "MRRBY".
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, risk factors, or contingencies. The sole purpose of the report is to disclose the change in the ADR trading symbol and incorporate the associated press release by reference.
Investor Verification Checklist
- Verify the new OTC trading symbol "CLSXY" for Celsus Therapeutics PLC ADRs.
- Confirm the effective date of the symbol change (September 16, 2013).
- Review the attached press release (Exhibit 99.1) for any additional context regarding the name change or corporate restructuring implied by the symbol shift.